Protocol Ledger

NCT06112704 · Phase II · RECRUITING

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Interventional Phase II clinical trial protocol NCT06112704 sponsored by Hansoh BioMedical R&D Company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-02-06 Enrollment: 220 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06112704
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)220 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06112704
Protocol FieldVerified Registry Value
NCT IdentifierNCT06112704
Consolidated Lead SponsorHansoh BioMedical R&D Company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment220 participants (ESTIMATED)
Registered Start Date2024-02-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06112704
Hospital Research SiteLocationSite Profile
Anhui Provincial Cancer HospitalHefei, ChinaOpen Hospital Dossier ->
Guangdong Provincial People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->
Harbin Medical University Cancer HospitalHarbin, ChinaOpen Hospital Dossier ->
Henan Cancer HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI